Chemotherapy of thyroid carcinoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Chemotherapy for thyroid carcinoma is typically a last resort after conventional treatments fail.
• Certain undifferentiated thyroid carcinomas may benefit from upfront chemotherapy.

Purpose of the Study:

• To review the current status of chemotherapy for thyroid carcinoma.
• To evaluate the efficacy of different chemotherapeutic agents and strategies.

Main Methods:

• Analysis of 8 patient cases and a comprehensive literature review.
• Evaluation of commonly used cytostatics including adriamycin, bleomycin, and cis-platinum.

Main Results:

• Adriamycin monotherapy appears superior to other treatments, except possibly for undifferentiated types.
• 4'-epi-adriamycin shows promise due to lower toxicity and potential for higher doses.
• Approximately one-third of thyroid carcinomas respond to adriamycin, with varying response rates by subtype and metastasis location.
• Chemotherapy response can extend median survival from 3-5 months to 15-20 months.

Conclusions:

• Chemotherapy is indicated for progressing thyroid cancer post-conventional therapy.
• Adriamycin monotherapy is a key treatment option, with dose optimization crucial for efficacy.
• 4'-epi-adriamycin offers a potentially safer and more prolonged treatment course.